Keyphrases
Systemic Lupus Erythematosus
100%
Lupus Anticoagulant
33%
Geriatric Patients
33%
Neuromuscular Electrical Stimulation
33%
Systemic Lupus Erythematosus Patient
25%
Disease Activity
23%
Quality of Life
19%
Echocardiographic
16%
Cardiovascular Autonomic Neuropathy
16%
Myocardial Fibrosis
16%
Left Ventricular Function
16%
Left Ventricular Size
16%
Cardiovascular Autonomic Dysfunction
16%
Investigator-initiated Clinical Trial
16%
Systemic Lupus Erythematous
16%
Type II Interferon
16%
Leg Lean Mass
16%
Transcutaneous Vagus Nerve Stimulation
16%
Novel Treatments
16%
Stimulator of Interferon Genes (STING)
16%
Vagus Nerve Stimulation
16%
Sham Control
16%
Functional Training
16%
Electrical Stimulation
16%
Changes in Structures
16%
Early Development
16%
Pathological Changes
16%
Tendinopathy
16%
Training Program
16%
Tissue Turnover
16%
Coronary Artery Calcification
16%
Longitudinal Cohort Study
16%
Renal Involvement
16%
Healthy Controls
16%
Hospitalization
14%
Lean Mass
12%
Disease Duration
9%
Lupus Nephritis
8%
Clinical Disease Activity
8%
5-year Follow-up
8%
Late Gadolinium Enhancement
8%
Muscle Activation
8%
Satellite Cells
8%
Fiber Size
8%
Cell number
8%
Gene Expression
7%
IFN Signature
7%
Diastolic Function
7%
Tendon
7%
Chronic Autoimmune Diseases
6%
Medicine and Dentistry
Systemic Lupus Erythematosus
66%
Lupus Anticoagulant
33%
Vagus Nerve Stimulation
16%
Clinical Trial
16%
Neuromuscular Electrical Stimulation
16%
Leg
16%
Cardiac Fibrosis
16%
Geriatrics
16%
Tendinosis
16%
Coronary Artery Calcification
16%
Cohort Analysis
16%
Disease Activity
12%
Disease Duration
8%
Gadolinium
8%
Autoimmune Disease
7%
Diastolic Function
7%
Lupus Nephritis
6%
Disease
5%
